Volume 199 - Issue 7
Treatment outcomes for Indigenous and non-Indigenous inmates with hepatitis C in New South Wales prisons
Authors: Jeffrey J Post, Andrew R Lloyd and Denise Monkley
Med J Aust 2013; 199 (7): 464. || doi: 10.5694/mja13.10925
Published online: 7 October 2013
Published online: 7 October 2013
New South Wales prisons data add to previous findings which show that Indigenous and non-Indigenous Australians achieve similar hepatitis C treatment outcomes.
To the Editor: Davis and colleagues recently described outcomes for Indigenous and non-Indigenous people in the Northern Territory who received antiviral therapy for chronic hepatitis C virus (HCV) infection.1 They showed similar outcomes when comparing eight Indigenous people with 88 non-Indigenous people who were assessed for sustained virological response (SVR) after interferon-based treatment — SVR was achieved by 50% and 61%, respectively. Outcomes of therapy for HCV infection in Indigenous Australians had not previously been reported.
Here, we extend this observation by reporting the outcomes from a de-identified database held by the hepatitis service of the Justice Health and Forensic Mental Health Network in New South Wales. As these data were de-identified and collected for quality assurance purposes, ethics approval was not sought.
Treatment services for HCV infection have been available in NSW correctional centres for more than a decade.2,3 Of 788 people treated with pegylated interferon and ribavirin over the period May 2002 to December 2012, 136 (17.3%) were Indigenous (Box). During this period, 16.9%–22.9% of inmates in NSW were Indigenous.4 Those receiving treatment were recorded as Indigenous (ie, Aboriginal or Torres Strait Islander), white and of English-speaking background, or from a culturally and linguistically diverse background. There were no differences between these groups in the distribution of viral genotypes (predominantly 1 and 3) and the SVR rates were closely comparable, although the proportion of women (who have more favourable treatment outcomes) was higher in the Indigenous patient group.
It is unfortunate, but encouraging, that a period of incarceration can provide the opportunity for curative treatment for HCV infection, and that similar outcomes are achieved by Indigenous and non-Indigenous inmates. The advent of simpler and better tolerated interferon-free therapies for HCV infection in the next few years will further enhance this treatment opportunity.
Comparison of age, sex, HCV genotype and treatment outcomes for white English-speaking, Indigenous and CALD prison inmates who received interferon-based treatment for HCV infection, New South Wales, 2002–2012*
Competing interests
No relevant disclosures.
References
- Davis JS, Kulatunga AC, Hajkowicz K. Outcomes for Indigenous and non-Indigenous patients who access treatment for hepatitis C in the Top End of the Northern Territory [letter]. Med J Aust 2013; 199: 23. 0_CHDDAJFG
- Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust 2010; 192: 496-500. 0_i1143099
- Lloyd AR, Clegg J, Lange J, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013; 56: 1078-1084. 0_i1143103
- Australian Bureau of Statistics. Prisoners in Australia. Canberra: ABS, 2013. (ABS Cat. No. 4517.0.) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/4517.02012?Open Document (accessed Jul 2013).
Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning
Savio G. Barreto, Christos S. Karapetis, Shahid Ullah, Matthew Burge, Susan Caird, Angus Campbell, Azim Jalali, Ross Jennens, Muhammad A. Khattak, Belinda Lee, Stephanie H. Lim, Shehara Mendis, Louise Nott, Timothy J. Price, Jeremy D. Shapiro, Jeanne Tie, Javier Torres, Colin Williams, Rachel Wong, Vanessa Wong, Peter Gibbs
Australian Pathways for Specialist Pain Management and Early Palliative Care for People With Pancreatic Cancer: Developed Using a Community Consensus Approach
Jennifer Philip, Melanie R. Lovell, Kylee Bellingham, Gail Garvey, Gregory B. Crawford, Nicole M. Rankin, Kara Burns, Isabel Young, Vivienne Milch, Dorothy Keefe, Katrina Anderson, James Lawson, Meinir Krishnasamy
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery
Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations
Jacob George, Nicole L Allard, Stuart K Roberts, Leon A Adams, Jane Davies, Behzad Hajarizadeh, Jennifer H MacLachlan, Suzanne E Mahady, Rosalie Altus, Catherine Brown, David C Fry, Belinda Greenwood‐Smith, Natali Smud, Patricia C Valery, Nafisa Yussf, Kate Broun, Denise Campbell, Karen Canfell, Chelsea Carle Harrison, Victoria Freeman, Paul Grogan, Catherine Holliday, Suzanne Hughes, Anna Kelly, Cathelijne Kemenade, Claire Latumahina, Amanda McAtamney, Megan Varlow, Joachim Worthington, Susan Yuill, Eleonora Feletto
Assessment of metabolic dysfunction‐associated fatty liver disease in primary care: a consensus statement summary
Leon A Adams, William W Kemp, Kate R Muller, Elizabeth E Powell, Stuart K Roberts, Luis Calzadilla Bertot, Stephanie Best, Gary Deed, Jon D Emery, Samantha L Hocking, Graham R Jones, John S Lubel, Sinead Sheils, Stephen M Twigg, Gerald F Watts, Jacob George
Treatment outcomes for people with hepatitis C referred to tertiary care in Victoria, 2021–22: a retrospective observational study
Elly Layton, Nicole Matthews, Brendan Quinn, Nasra Higgins, Gabrielle Lindeman, Mielle Abbott, Jennifer MacLachlan, Elizabeth Birbilis, Margaret E Hellard, Joseph Doyle, Benjamin C Cowie, Mark Stoové